The natural history of ductal carcinoma in situ of the breast: a review

2005 ◽  
Vol 97 (2) ◽  
pp. 135-144 ◽  
Author(s):  
Bircan Erbas ◽  
Elena Provenzano ◽  
Jane Armes ◽  
Dorota Gertig
2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Sarocha Chootipongchaivat ◽  
Nicolien T. van Ravesteyn ◽  
Xiaoxue Li ◽  
Hui Huang ◽  
Harald Weedon-Fekjær ◽  
...  

Author(s):  
Samantha L Heller ◽  
Anastasia Plaunova ◽  
Yiming Gao

Abstract Ductal carcinoma in situ (DCIS), breast cancer confined to the milk ducts, is a heterogeneous entity. The question of how and when a case of DCIS will extend beyond the ducts to become invasive breast cancer has implications for both patient prognosis and optimal treatment approaches. The natural history of DCIS has been explored through a variety of methods, from mouse models to biopsy specimen reviews to population-based screening data to modeling studies. This article will review the available evidence regarding progression pathways and will also summarize current trials designed to assess DCIS progression.


Mastology ◽  
2018 ◽  
Vol 28 (2) ◽  
pp. 114-118
Author(s):  
Nayara Alves de Freitas Lemos ◽  
◽  
Ruffo Freitas- Junior ◽  
Marise Amaral Rebouças Moreira ◽  
Fábio Francisco Oliveira Rodrigues ◽  
...  

2018 ◽  
Vol 38 (1_suppl) ◽  
pp. 126S-139S ◽  
Author(s):  
Nicolien T. van Ravesteyn ◽  
Jeroen J. van den Broek ◽  
Xiaoxue Li ◽  
Harald Weedon-Fekjær ◽  
Clyde B. Schechter ◽  
...  

Background. Ductal carcinoma in situ (DCIS) can be a precursor to invasive breast cancer. Since the advent of screening mammography in the 1980’s, the incidence of DCIS has increased dramatically. The value of screen detection and treatment of DCIS, however, is a matter of controversy, as it is unclear the extent to which detection and treatment of DCIS prevents invasive disease and reduces breast cancer mortality. The aim of this paper is to provide an overview of existing Cancer Intervention and Surveillance Modelling Network (CISNET) modeling approaches for the natural history of DCIS, and to compare these to other modeling approaches reported in the literature. Design. Five of the 6 CISNET models currently include DCIS. Most models assume that some, but not all, lesions progress to invasive cancer. The natural history of DCIS cannot be directly observed and the CISNET models differ in their assumptions and in the data sources used to estimate the DCIS model parameters. Results. These model differences translate into variation in outcomes, such as the amount of overdiagnosis of DCIS, with estimates ranging from 34% to 72% for biennial screening from ages 50 to 74 y. The other models described in the literature also report a large range in outcomes, with progression rates varying from 20% to 91%. Limitations. DCIS grade was not yet included in the CISNET models. Conclusion. In the future, DCIS data by grade from active surveillance trials, the development of predictive markers of progression probability, and evidence from other screening modalities, such as tomosynthesis, may be used to inform and improve the models’ representation of DCIS, and might lead to convergence of the model estimates. Until then, the CISNET model results consistently show a considerable amount of overdiagnosis of DCIS, supporting the safety and value of observational trials for low-risk DCIS.


Sign in / Sign up

Export Citation Format

Share Document